Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics Limited (BCYC) is a clinical-stage biopharmaceutical leader pioneering targeted oncology treatments through its proprietary Bicycle® peptide platform. This page serves as the definitive source for verified company updates, offering investors and researchers centralized access to essential developments.
Track BCYC's progress in creating novel therapies that combine antibody-like precision with small molecule efficiency. Our news collection features:
• Clinical trial milestones for oncology candidates
• Strategic partnership announcements
• Regulatory updates across US and EU markets
• Platform technology enhancements
All content undergoes rigorous verification to ensure accuracy in reporting scientific advancements and corporate developments. Bookmark this page for real-time updates on BCYC's mission to redefine cancer treatment paradigms through innovative peptide engineering.
Bicycle Therapeutics (NASDAQ: BCYC) reported its Q4 and full-year 2024 financial results and recent business progress. Updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer showed a 65% overall response rate among 20 efficacy evaluable patients. Enhanced response was observed in NECTIN4 gene-amplified breast and lung cancers, leading to FDA Fast Track designations. Several Phase 1/2 trials are expected in 2025.
The company is advancing its radiopharmaceuticals pipeline with additional MT1-MMP human imaging data expected mid-2025 and first EphA2 human imaging data planned for 2H 2025. Cash and cash equivalents were $879.5 million as of December 31, 2024, providing financial runway into 2H 2027.
R&D expenses were $49.8 million for Q4 and $173.0 million for the year, while G&A expenses were $21.6 million for Q4 and $72.2 million for the year. Net loss was $51.9 million for Q4 and $169.0 million for the year, compared to $49.1 million and $180.7 million, respectively, in 2023.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat on Wednesday, February 12, at 10 a.m. ET.
The event will be accessible through a live webcast available on the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). For those unable to attend live, a replay of the webcast will be archived and made available after the event.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the approval of inducement awards for 18 new employees by its Board's Compensation Committee. The awards, granted on February 3, 2025, consist of non-qualified share options to purchase a total of 117,300 ordinary shares under the company's 2024 Inducement Plan.
The options have an exercise price of $13.39 per share, matching Bicycle's closing price on January 31, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment.
Bicycle Therapeutics (NASDAQ: BCYC) announced updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer (mUC). The combination showed a 65% overall response rate among efficacy-evaluable patients, with 50% confirmed responses in 20 patients. The safety profile remained consistent with previous studies, with no patient withdrawals due to treatment-related adverse events.
The company outlined its 2025 strategic priorities, including expanding zelenectide pevedotin trials across multiple Nectin-4 associated cancers, with Phase 1/2 trials planned in breast cancer, lung cancer, and multiple tumors. Additional milestones include reporting Phase 2/3 Duravelo-2 dose selection data and advancing their radiopharmaceuticals pipeline.
As of September 2024, Bicycle reported $890.9 million in cash and cash equivalents, with an expected financial runway into second half of 2027.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, which will be followed by a Q&A breakout session at 5:35 p.m. PT.
Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website at www.bicycletherapeutics.com. The company will also make a replay of the webcast available on their website after the event.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to 12 new employees. The awards, approved by the Compensation Committee of the company's Board of Directors on January 2, 2025, consist of non-qualified share options to purchase a total of 67,300 ordinary shares.
The options were granted under Bicycle's 2024 Inducement Plan with an exercise price of $14.00 per share, matching the company's closing price on December 31, 2024. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Inducement Plan terms and conditions.
Bicycle Therapeutics (NASDAQ: BCYC) announced significant data updates for its zelenectide pevedotin program. The drug showed a 60% overall response rate when combined with pembrolizumab in first-line metastatic urothelial cancer. In breast cancer patients with NECTIN4 gene amplification, the drug demonstrated a 62.5% response rate, while NSCLC patients with NECTIN4 gene amplification showed a 40% response rate.
The company plans to advance its development strategy focusing on NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer, and multi-tumor planned for 2025. Dose selection and topline data from the Phase 2/3 Duravelo-2 trial are expected in 2H 2025.
Bicycle Therapeutics (NASDAQ: BCYC) has expanded its Clinical Advisory Board with three distinguished oncology experts to support its clinical oncology programs development. The new members include: Howard A. 'Skip' Burris III, president and chief medical officer of Sarah Cannon Research Institute; Markus Eckstein, senior consultant pathologist at University Hospital Erlangen; and Niklas Klümper, senior consultant for Urology & Genitourinary Oncology at University Hospital Bonn.
Each expert brings specialized experience: Burris in first-in-human therapies and FDA-approved treatments, Eckstein in genitourinary pathology and systems immunology, and Klümper in precision oncology and drug conjugate development.
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to thirteen new employees on December 2, 2024. The awards consist of non-qualified share options to purchase 62,400 ordinary shares at an exercise price of $20.40 per share. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months. These grants were made under the company's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) announced upcoming presentations of data for zelenectide pevedotin at the 2024 San Antonio Breast Cancer Symposium. The company will present findings showing enhanced anti-tumor activity in triple-negative breast cancer patients with NECTIN4 gene amplification.
Additionally, Bicycle will announce topline data for zelenectide pevedotin plus pembrolizumab combination in first-line metastatic urothelial cancer patients, and monotherapy results in non-small cell lung cancer patients. The poster presentation, led by Dr. Niklas Klümper from University Hospital Bonn, is scheduled for December 12. A conference call to discuss these updates will be held on December 13.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
